Bevacizumb in patients with metastatic colorectal cancer: access and performance in Uruguay
Colorectal cancer is the third in frequency and the second leading cause of death from cancer in Uruguay. Bevacizumab is a recombinant humanized monoclonal antibody to vascular endothelial growth factor. It is funded, with
centralized and universal coverage, for metastatic colorectal cancer patients in Uruguay. A regulatory framework for coverage and a systematic process of evaluation were established. Objective: Assess the access, effectiveness and tolerance of Bevacizumab associated with chemotherapy in patients with metastatic colorectal cancer in first or subsequent line of treatment.
Colorectal cancer is the third in frequency and the second leading cause of death from cancer in Uruguay. Bevacizumab is a recombinant humanized monoclonal antibody to vascular endothelial growth factor. It is funded, with
centralized and universal coverage, for metastatic colorectal cancer patients in Uruguay. A regulatory framework for coverage and a systematic process of evaluation were established. Objective: Assess the access, effectiveness and tolerance of Bevacizumab associated with chemotherapy in patients with metastatic colorectal cancer in first or subsequent line of treatment.
Autores:
Dr. Henry Albornoz, MSc. Gustavo Saona, Dr. Fernando Correa, Dr. Abayubá Perna, Dra. Eliana Lanzani. Dr. Henry Albornoz, MSc. Gustavo Saona, Dr. Fernando Correa, Dr. Abayubá Perna, Dra. Eliana Lanzani.
Tipo de publicación:
P. CIENTÍFICAS - Póster y Presentaciones